Skip to content
MarketScale
‹ Back to IndustriesSciences

Can Scientists Use ChatGPT for Scientific Research?

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · Ai ToolsArtificial IntelligenceChatgptResearch Methods
Share

Key takeaways

01

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers.

02

The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient. Surprisingly for the academic community, the experiment proved successful, with their research finding that OpenAI’s models “can capture the concepts in the scholarly text and produce high-quality revisions that improve clarity.” More readable and accessible academic manuscripts sounds like a win for everyone involved, but how else can AI-supported chatbots support the academic community? Greene and Pividori’s research leaves many wondering whether scientists dealing in rigorous and highly-technical subjects can leverage ChatGPT for scientific research from start to finish.

ChatGPT was launched in November 2022 and got over 1 million users within the first week of its launch; OpenAI’s tool is clearly highly popular and gaining mainstream appeal, validating new use cases every week. The tool can perform complex tasks that save loads of time and energy, and can produce text like poetry, prose, computer code, and even topical research ideas. However, it’s not a perfect tool by any stretch. High level thought leaders in the tech community, including Steve Wozniak, warn that ChatGPT’s text generation can be riddled with errors. Obviously, anything of academic quality can’t have erroneous revisions applied.

Scientists use various types of research methods to gather information to develop their hypotheses and supplement academic texts, including digging for sources, conducting hypothetical scientific models to prove their research, running surveys for new data, and more. With ChatGPT Plus hot on our heels, should scientists start to use ChatGPT for scientific research? How confident can they be in its efficacy? Justin Bean, author of What Could Go Right and an experienced sustainability and smart city strategist working with Fortune 500s and cutting-edge start-ups, weighs in with his take. Bean is highly familiar with the research process; he spent many years as a clean tech and green energy consultant, where he conducted layered and rigorous research of financial data, venture capital investments, trend reports and more.

Justin’s Thoughts:

“So, if Siri gave everyone a digital assistant, ChatGPT gives everyone a digital intern. This means it can do way more work for us and including in science. So, a lot of the work in science and data analysis is all about gathering and blending and cleaning and compiling data, and about making interpretations that lead to some kind of insight, which they can then take and do science with.

Now because of ChatGPT, a lot of that early stage can be done by an AI and that’ll free up scientists to have a lot more time doing the science. But not just that, it’s going to free a lot of people up to be able to do science who aren’t conventional scientists and people who don’t have PhDs. This is because it’s going to do a lot of that initial work and be able to explain it in everyday layman’s terms for you and me to be able to do the science.

And I think that’s going to democratize a lot of inventions and a lot of science as innovators from around the world and different perspectives, it will bring their perspectives to science and leverage the information they can get through chatGPT. Now, as this develops, all these AIs are going to become more and more specialized.

So you may have a specialized artificial intelligence for cancer science and detection, and another one for weather science or climate science. Many different ones will proliferate. In addition, we’re going to have autonomous economic agents that will take that information and go out and acquire materials or goods or contracts for us just to make a lot of that process a lot easier and make us all more effective.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512